NRG ONCOLOGY NETWORK GROUP OPERATIONS CENTER

NRG 肿瘤网络集团运营中心

• 批准号: 8839743
• 负责人: WALTER J. CURRAN
• 金额: $ 1691.12万
• 依托单位: NRG ONCOLOGY FOUNDATION, INC.
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-17 至 2019-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8839743
• 关键词: Adult; Biological Markers; Brain Neoplasms; Cancer Control; Cancer Control Research; Cancer Survivorship; Caring; Clinical Research; Clinical Trials; Colorectal Cancer; Decision Making; Development; Developmental Therapeutics Program; Diagnostic; Diagnostic Neoplasm Staging; Disease; Endometrial Carcinoma; Enrollment; Gender; Gynecologic Oncology Group; Head and Neck Cancer; Image; Information Technology; Investigational Therapies; Knowledge; Leadership; Malignant Female Reproductive System Neoplasm; Malignant Neoplasms; Malignant neoplasm of cervix uteri; Malignant neoplasm of gastrointestinal tract; Malignant neoplasm of lung; Malignant neoplasm of ovary; Malignant neoplasm of prostate; Medical Technology; Mission; Modeling; Multi-Institutional Clinical Trial; National Clinical Trials Network; National Surgical Adjuvant Breast and Bowel Project; Operative Surgical Procedures; Outcomes Research; Pathway interactions; Patient Care; Patient-Focused Outcomes; Patients; Phase; Phase II/III Trial; Primary Brain Neoplasms; Process; Protocols documentation; Radiation Oncology; Radiation Therapy Oncology Group; Randomized; Recording of previous events; Regulation; Research; Resources; Risk; Stratification; Systemic Therapy; Technology; Testing; Therapeutic; Therapeutic Human Experimentation; Therapeutics Committee; Translational Research; Urogenital Cancer; Vision; base; biobank; cancer prevention; clinical decision-making; data management; design; improved; innovation; knowledge base; malignant breast neoplasm; novel; oncology; operation; phase III trial; programs; public health relevance; success; tumor

DESCRIPTION (provided by applicant): NRG Oncology is a newly constituted NCI National Clinical Trials Network (NCTN) network group created through the coordinated efforts of the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG) with a primary vision of improving the lives of adult patients with localized or locally advanced malignancies through the conduct of high quality NCI-supported multi-institutional clinical trials. NRG Oncology (or NRG) has leveraged the tremendous resources, leadership, membership, and history of practice-defining research of the three legacy groups to create a modern clinical and translational research organization with the capability to execute clinical and translational research trials for adult patients with common and rare malignancies in the following disease sites: Gynecologic Cancer (including Ovarian, Cervix and Endometrial Cancer); Brain Tumors (Primary and Secondary); Breast Cancer; Gastrointestinal Cancers (Colorectal and Non-Colorectal Cancers); Genitourinary Cancer; Head and Neck Cancer; and Lung Cancer. NRG will be the leading network group defining new standards of care and scientific paradigms for several of these disease sites. For these seven cancer disease sites, NRG will primarily conduct trials for patients with early or intermediate stage cancers testing innovative diagnostic and therapeutic approaches, including novel imaging, radiation oncology, and surgical approaches; the integration of novel systemic agents or classes of systemic agents with optimized loco-regional therapies and existing systemic therapies, and the use of biomarker- and biologic pathway-defined approaches to risk stratification, investigational therapy assignment, and clinical trial decision-making. The group has seven scientific core committees and four integrated committees which provide both scientific support and generate protocols: Developmental Therapeutics (DT), Translational Science, Patient-Centered Outcomes Research, and Cancer Prevention and Control Committees. NRG's DT Committee builds on the GOG DT Committee's success in enrolling over 500 patients/year on early phase trials leading to phase III trials. The NRG Operations Center is fully aligned with NRG Oncology Statistical and Data Management Center (SDMC) and the NRG Biorepositories and will be fully compliant with all NCI regulations and proactive in improving the efficiency and quality of its research. The group will serve as a scientific resource for other NCTN network groups for radiation oncology innovation through its Center for Innovative Radiation Oncology (CIRO).

描述（由申请人提供）：NRG肿瘤学是一个新成立的NCI国家临床试验网络（NCTN）网络组，是通过国家手术辅助乳腺癌和肠项目（NSABP）的协调努力创建的，放射治疗疗法肿瘤学组（RTOG）以及与跨科学组织（GOGOLIC ONCOLIGIC ONCOLIGIAL ONCOLIGIAL GORTISER COMPTINAL COMPRIAN COMPTIAN COMPTIAN COMPTIAN COMPTIAN COMPTIAN COMPTIAN COMPTIAN COMPTIAN COMPTIAN COMPOLIC ONCOLIGIAL ONCOLIGIAL ONCOLIGIAL ONCOLIDIAL GORTINGIAL）的生活。通过进行高质量NCI支持的多机构临床试验的恶性肿瘤。 NRG肿瘤学（或NRG）利用了三个遗产小组的研究定义研究的大量资源，领导力，会员和历史，以创建一个现代的临床和转化研究组织，能够执行临床和转化研究试验，以针对以下疾病癌症，包括Ovial癌症，Cervarians和Overcary，Cervarians，包括OVIAL，CORVARIANS，CARNETATION，包括Ovial cancer和Endertation，coverallance consection and concercant and overance;脑肿瘤（原发性和继发性）；乳腺癌;胃肠癌（结直肠癌和非色直肠癌）；泌尿生殖器癌；头颈癌；和肺癌。 NRG将是为其中几个疾病部位定义新的护理和科学范式的领先网络组。对于这七个癌症疾病部位，NRG将主要针对患有早期或中期癌症患者测试创新诊断和治疗方法的患者进行试验，包括新型成像，放射肿瘤学和手术方法；新型的系统性药物或全身性药物类别与优化的机能区域疗法和现有的全身疗法的整合，以及使用生物标志物和生物学途径定义的方法，用于风险分层，研究疗法分配和临床试验决策。该小组有七个科学核心委员会和四个综合委员会，这些委员会既提供科学支持又产生协议：发育治疗学（DT），转化科学，以患者为中心的结果研究以及预防癌症和控制委员会。 NRG的DT委员会建立在GOG DT委员会成功地招募500多名患者参加的早期试验中，导致III阶段试验的早期试验。 NRG操作中心与NRG肿瘤学统计和数据管理中心（SDMC）和NRG生物局局完全一致，并将完全符合所有NCI法规，并积极主动提高其研究的效率和质量。该小组将通过其创新辐射肿瘤学中心（CIRO）作为其他NCTN网络组的科学资源。